Accentia Biopharmaceuticals
Advanced Immunotherapeutics
Learn More
Francis E. O'Donnell, Jr. MD
Chairman and CEO
Dr. O'Donnell has served as Chairman of the Board of Accentia Biopharmaceuticals, Inc. since November, 1998 and as CEO since May 2003. Dr O'Donnell is a 1975, summa cum laude graduate of the Johns Hopkins School of Medicine. He received his specialty training at the Wilmer Ophthalmological Institute, Johns Hopkins Hospital. He is the former Professor and Chairman, Dept of Ophthalmology, St Louis University School of Medicine. He is the Founder and Managing Partner of The Hopkins Capital Group (HCG), LLC, a leading biotech investment/business development company. The HCG specializes in early-stage investments in disruptive innovations in healthcare. Dr O'Donnell has published over 30 peer-reviewed scientific articles and he has been awarded 34 US Patents. He is the recipient of the 2000 Jules Stein Award from Retinitis Pigmentosa International.
Samuel S. Duffey, Esq.
President and General Counsel
Named as President in December 2008, Mr. Duffey, has also served as our General Counsel since April 2003. Prior to that, Mr. Duffey practiced business law with Duffey and Dolan P.A. beginning in 1992. From February 2000, to September 2003, Mr. Duffey served as the non-executive chairman and as a member of the board of directors of Invisia, Inc., a small publicly held safety company, and from October 2001 to May 2004, Mr. Duffey also served as the non-executive chairman and as a member of the board of directors of FlashPoint International, Inc., a publicly held automotive parts company which is currently named Navitrak International Corporation. Mr. Duffey received his B.A. and J.D. degrees from Drake University.
Alan M. Pearce
Chief Financial Officer
Mr. Pearce recently retired as Senior Vice President, Financial Services of McKesson Corporation after 27 years with the firm. McKesson Corporation, a publicly traded Fortune 20 company (NYSE: MCK), is the leading provider of supply, information and care management products and services designed to reduce costs and improve quality across healthcare. Mr. Pearce held his last position since April 1999. Prior to this date he was treasurer of McKesson Corporation. Mr. Pearce currently serves on the board of directors and a member of the audit committee of BioDelivery Sciences International, Inc., a publicly traded drug delivery technology company (NASDAQ: BDSI). Mr. Pearce also currently serves on the advisory boards of Georgia Tech-Emory University BioEngineering Foundation and Hopkins Capital Group, a venture capital firm specializing in the healthcare field, and has previously served as a director and a member of the finance committee of XL Insurance. He is a graduate of Georgia Institute of Technology, where he earned a BS in Industrial Management and University of Texas, where he earned his MBA in finance.
James A. McNulty, CPA
Treasurer and Corporate Secretary
Mr. McNulty serves as Chief Financial Officer of Hopkins Capital Group, an affiliation of limited liability companies which engage in venture activities and is an active investor in Accentia. He also serves as Chief Financial Officer of BioDelivery Sciences International, Inc. (Nasdaq: BDSI). Mr. McNulty practiced public accounting from 1971 through 1997 and co-founded Pender McNulty & Newkirk, which became one of Florida's largest regional CPA firms and was a founder/principal in two other CPA firms. He served as Chief Financial Officer of Star Scientific, Inc. (Nasdaq: STSI) from October 1998 to May 2000. From June 2000 through January 2002, he served as Chief Financial Officer and Chief Operating Officer of American Prescription Providers, Inc. Mr. McNulty is a graduate of University of South Florida, a licensed Certified Public Accountant and a member of the American and Florida Institutes of CPAs.
Carlos F. Santos, Ph.D.
Chief Scientific Officer
Since 1998, Dr. Santos has provided on pharmaceutical product development, intellectual property and regulatory strategy design and informatics and analytical research for The Hopkins Capital Group and its portfolio companies, Accentia Biopharmaceuticals, Inc. and Biodelivery Sciences International (NASDAQ:BDSI). He currently serves as the CEO of Retinapharma Technologies (www.retinapharma.com), a privately-held Hopkins Capital Group portfolio company developing therapeutics for the prevention, treatment, rescue and recovery of neurodegenerative and neurovascular ophthalmic diseases. At the University of Michigan, he developed automated natural language processing systems for the integration of high-throughput genomic and proteomic databases with the biomedical literature. He also lead the development of a large-scale automated search and summarization engine at the University of Michigan's National Center for Integrative Biomedical Informatics (NCIBI). From 1998 to 2001, he was a researcher at Washington University in St. Louis' Institute for Biomedical Computing (IBC). He is a graduate of Washington University in Saint Louis's Sever School of Engineering and WU's School of Arts and Sciences, where he received a BS in Computer Science, majoring also in Biology. Dr. Santos received a Ph.D. in Bioinformatics from the University of Michigan.